Article

Prostate cancer grading: The effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade

UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland.
BJU International (Impact Factor: 3.13). 10/2009; 105(5):631-5. DOI: 10.1111/j.1464-410X.2009.08810.x
Source: PubMed

ABSTRACT To assess the discrepancy between needle biopsy (NB) and radical prostatectomy (RP) Gleason score (GS) in Irish men, specifically the influence of the stratification of GS 4 + 3 on overall levels of agreement, levels of discrepancy and kappa coefficients, as the GS assigned to prostate cancer NBs affects clinical decision-making and influences future therapeutic strategies.
We reviewed retrospectively a database of the discrepancies between NB and RP Gleason grades (GG) from 2003 to 2008. All patients had clinically localized prostate cancer, and none had had neoadjuvant therapy. Grading of 206 NB specimens was compared with their corresponding RP specimens. The discrepancy rate between NB and RP GS was assessed for each combination of GG. Intermediate- (GS 7, defined as GS 3 + 4 alone vs GS 7) and high-grade (GS 4 + 3 and GS 8-10 vs GS 8-10) classifications were compared. The level of agreement and the kappa coefficient for each system was assessed.
In NB, GS 6 was most frequently diagnosed (53%); after RP, GS 3 + 4 was most frequent (36%). In 42% of cases the exact GG remained unchanged after RP, increasing to 48% for GS 6 and GS 3 + 4. Overall 42% of cases showed an increase in their GG. In GS 6 NBs, the rate of increase in the primary GG or increase in the GS was 52%. Biopsy GS 6 and 3 + 4 showed the highest levels of agreement between NB and RP. Low-grade prostate cancer on NB was upgraded in 52% of cases; high-grade prostatic adenocarcinoma was downgraded in 27-77% of cases depending on the grading system used.
Classification of high-grade prostate cancer as GS 4 + 3 and GS 8-10 results in higher levels of agreement between NB and RP GS. Reliable identification of well differentiated prostatic adenocarcinoma in NB specimens represents an ongoing diagnostic challenge, necessitating careful preoperative consideration of the definitive grade of a patient's disease.

0 Followers
 · 
91 Views
  • Source
    • "Altered glycosylation in Gleason stages is consistent with clinical data The outcome of prostate cancer patients is significantly correlated with the Gleason score. Patients with Gleason score 7 (high-grade disease) is more commonly found to have advanced disease, and thus, the likelihood of relapse is higher than patient with low-grade prostate cancer (Fanning et al. 2010). We found a decrease in triantennary trigalactosylated glycans and in tetraantennary tetrasialylated outer armfucosylated glycans and increase in tetraantennary tetrasialylated glycans in Gleason 7 compared with Gleason 5 prostate cancer patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the most urgent requirements in prostate cancer diagnosis is the development of a blood-based test which would be able to distinguish prostate cancer from benign prostate hyperplasia (BPH). Previously published results found a significant difference between specific glycan levels in patients with advanced prostate cancer and healthy controls. N-Glycans from the whole serum glycoproteins were measured using our fully quantitative high-throughput N-glycan analysis in combination with exoglycosidase digestions in sera from 13 BPH and 34 prostate cancer samples (17 Gleason score 5 and 17 Gleason score 7). The levels of core-fucosylated biantennary glycans and α2-3-linked sialic acids were significantly increased in prostate cancer patients compared with patients with BPH. Triantennary trigalactosylated glycans and tetraantennary tetrasialylated glycans with outer arm fucose were significantly decreased, and tetraantennary tetrasialylated glycans increased in Gleason 7 compared with Gleason 5. All these glycans can distinguish prostate cancer patients from BPH or Gleason 7 from Gleason 5 prostate cancer patients better than the current clinical test, prostate-specific antigen; therefore, their measurement may provide a new noninvasive approach to diagnose prostate cancer. However, additional validation studies would need to be carried out to further support this finding. Decreases in triantennary trigalactosylated glycans and/or bisected core-fucosylated biantennary monosialylated glycans and increases in tetraantennary tetrasialylated glycans correlate with perineural invasion, which could further help to diagnose tumor spread and predict patients' survival.
    Glycobiology 02/2011; 21(2):195-205. DOI:10.1093/glycob/cwq147 · 3.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The 5-tier Gleason grading system for prostate cancer, introduced in 1966, has been proven to be one of the main independent predictors of prostate cancer outcome. This review addresses interobserver concordance in Gleason grading; the persistence of grading discrepancies with frequent upgrading from the biopsy to the prostatectomy specimen; the 2005 International Society of Urologic Pathologists' modifications to Gleason grading; the impact of this modified grading on grade migration and outcome prediction; and molecular correlates of cancer morphology. Data from the most recent years are emphasized.
    Current Urology Reports 03/2011; 12(3):216-22. DOI:10.1007/s11934-011-0181-5 · 1.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, Prostate Specific Antigen (PSA) testing is widespread and has been associated with deceased mortality rates; however, this testing has raised concerns of overdiagnosis and overtreatment. It is clear that additional biomarkers are required. To identify these biomarkers, we have undertaken proteomics and metabolomics expression profiles of serum samples from BPH, Gleason score 5 and 7 using two-dimensional difference in gel electrophoresis (2D-DIGE) and nuclear magnetic resonance spectroscopy (NMR). Panels of serum protein biomarkers were identified by applying Random Forests to the 2D-DIGE data. The evaluation of selected biomarker panels has shown that they can provide higher prediction accuracy than the current diagnostic standard. With careful validation of these serum biomarker panels, these panels may potentially help to reduce unnecessary invasive diagnostic procedures and more accurately direct the urologist to curative surgery.
    Journal of Proteome Research 03/2011; 10(3):1361-73. DOI:10.1021/pr1011069 · 5.00 Impact Factor
Show more